<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82363">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988948</url>
  </required_header>
  <id_info>
    <org_study_id>2011-42</org_study_id>
    <secondary_id>2012-A00814-39</secondary_id>
    <nct_id>NCT01988948</nct_id>
  </id_info>
  <brief_title>Dynamics of Human PApilloma Virus Interactions; Internet-based Students HeAlth Research Enterprise</brief_title>
  <acronym>DyPAVIR</acronym>
  <official_title>Impact de la Vaccination Sur la Distribution Des génotypes de Papillomavirus (HPV) et Suivi de la Dynamique Intra-individuelle de l'Infection et Des Co-infections Dans Une Population d'étudiantes âgées de 18 à 20 Ans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Versailles Saint-Quentin-en-Yvelines</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>centre national de référence pour les Papillomavirus Humains</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human papillomavirus (HPV) infection is the most common sexually transmitted infection. The
      high risk oncogenic types, HPV-16 and -18 are responsible for 70% of cervical cancers. The
      introduction of vaccination against two major oncogenic genotypes of HPV raises questions
      about genotype replacement because of the existence of other oncogenic types not targeted by
      the vaccine. A better understanding of natural history of HPV infection and interaction
      (competition, synergy) between genotypes are required in order to anticipate this
      phenomenon.

      The aims of this study are to characterize HPV infection in young female students and to
      follow up HPV infection and co-infection dynamics with different genotypes, taking into
      account both vaccination status and immunity to HPV 16 and 18. The study also focuses on the
      determination of factors influencing the development of persistent cervical HPV infections.

      The DyPAVIR-ISHARE study is based on the participation of 5000 young female students, from
      18 to 20 years-old, all registered at the Universities of Bordeaux or Versailles
      Saint-Quentin (UVSQ). The 3-years follow-up includes completion of a self-administrated
      questionnaire regarding sexual behaviour, socio-demographic characteristics, access to
      health-care services and, for a sub-group of 1000 students, the taking of genital and oral
      self-taken samples for the detection and genotyping of HPV (every 3 months). Previously, a
      pilot phase study (2 visits in 3 months of interval) is set up on 50 young female students
      from UVSQ in order to test feasibility.

      This study will provide data to gain insight into the possibility of type replacement.
      Moreover, this study would provide an overview of HPV vaccine coverage and effectiveness HPV
      incidence and factors associated with HPV infection and co-infection ; Partners recruitment
      would allow us to follow HPV transmission dynamics among couples, and in particular, HPV
      exposure in young adult women. The HPV research won't be limited to virus detection in
      samples but will indicate the presence or absence of HPV infection.

      Finally, additional genetic studies could be conducted in order to study genetic
      susceptibility to HPV infection, to chronic HPV infection and to co-infection.

      This research project is part of the i-Share program funded by the &quot;Investissement d'Avenir&quot;
      cohort call.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Proportion of HPV detection at inclusion (all HPV genotypes)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of oncogenic HPV genotypes, co-infection with different HPV genotypes</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Factors associated with HPV infection and co-infection</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>HPV clearance (all genotypes and genotype-specific HPV)</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Infection by Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>student cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Various biological sampling
blood sampling,
oral, vulvar, vaginal and anal sampling for women,
oral and genital sampling for men</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Various biological sampling</intervention_name>
    <arm_group_label>student cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Women

        Inclusion Criteria:

          -  voluntary student consulting the health service of university

          -  age 18-20 y.o.

          -  informed consent signed

          -  affiliated to national health insurance

        Exclusion Criteria:

          -  pregnancy

          -  end of the pregnancy within the last 3 months

          -  Student participating in another clinical trial

        Men

        Inclusion Criteria:

          -  being the sexual partner of a woman included in this study

          -  at least 18 y.o

          -  informed consent signed

          -  affiliated to national health insurance

        Exclusion Criteria:

        none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Guillemot, Pr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Unité Pharmacoépidémiologie et maladies infectieuses (PhEMI), Institut Pasteur / Université Versailles Saint-Quentin-en-Yvelines / INSERM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabeth Delarocque-Astagneau, MD</last_name>
    <role>Study Director</role>
    <affiliation>Unité Pharmacoépidémiologie et maladies infectieuses (PhEMI), Institut Pasteur / UVSQ / Inserm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuelle Mathiot-Vicaigne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Versailles Saint-Quentin-en-Yvelines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service Universitaire de Médecine Préventive et de Promotion de la Santé (SUMPPS)</name>
      <address>
        <city>Versailles</city>
        <zip>78000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 14, 2013</lastchanged_date>
  <firstreceived_date>November 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human papilloma virus</keyword>
  <keyword>Young women</keyword>
  <keyword>I-Share</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
